Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Clinical Trials
756
Trial Phases
5 Phases
Drug Approvals
5
Clinical Trials
Distribution across different clinical trial phases (673 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
- Conditions
- Functional Hypothalamic Amenorrhea (FHA)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-11-19
- Last Posted Date
- 2025-11-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT07235917
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
- First Posted Date
- 2025-11-17
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT07230834
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2025-10-30
- Last Posted Date
- 2025-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 915
- Registration Number
- NCT07222761
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
- First Posted Date
- 2025-10-24
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT07220772
Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy
- Conditions
- Generalized Lipodystrophy
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-24
- Last Posted Date
- 2025-10-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT07220785
- Prev
- 1
- 2
- 3
- 4
- 5
- 73
- Next
News
FDA Approves Multiple New Cancer Therapies Including Bayer's Hyrnuo for NSCLC and Amgen's Imdelltra for Small Cell Lung Cancer
The FDA has approved Bayer's Hyrnuo (sevabertinib), an oral tyrosine kinase inhibitor for locally advanced or metastatic non-squamous non-small cell lung cancer in adults with HER2-activating mutations.
Formycon Achieves Technical Proof of Similarity for Dupilumab Biosimilar FYB208, Targeting $20 Billion Market
Formycon AG successfully completed the Technical Proof of Similarity (TPoS) for FYB208, demonstrating high analytical comparability to Dupixent (dupilumab).
Regeneron Announces $2 Billion Manufacturing Expansion in New York, Creating 1,000 Jobs
Regeneron Pharmaceuticals plans a $2 billion expansion in Saratoga Springs, New York, creating 1,000 permanent full-time jobs and 500 construction positions.
FDA-Approved Prostate Cancer Drugs Show Promise Against Acute Myeloid Leukemia in Preclinical Studies
Penn State researchers discovered that two FDA-approved prostate cancer drugs, apalutamide and finasteride, effectively suppressed acute myeloid leukemia progression in both male and female mice and patient-derived AML cells.
UK High Court Clears Path for Alvotech's Eylea Biosimilar Manufacturing Ahead of Patent Expiry
The UK High Court rejected Regeneron and Bayer's injunction request against Alvotech's manufacturing of AVT06, a biosimilar to Eylea (aflibercept), allowing continued production at the company's UK contract manufacturing organization.
AstraZeneca Acquires SixPeaks Bio for $300M to Advance Muscle-Preserving Obesity Treatments
AstraZeneca exercised its option to acquire obesity startup SixPeaks Bio for $170 million upfront, with an additional $30 million in two years and up to $100 million in regulatory milestone payments.
Libtayo Gains Widespread Provincial Reimbursement Across Canada for Advanced NSCLC and Basal Cell Carcinoma
Regeneron's PD-1 inhibitor Libtayo (cemiplimab) is now reimbursed by public drug programs in seven Canadian provinces for advanced non-small cell lung cancer and locally advanced basal cell carcinoma.
ModeX Therapeutics and Regeneron Partner on $1 Billion Multispecific Antibody Collaboration
ModeX Therapeutics, an OPKO Health subsidiary, has entered into a license and collaboration agreement with Regeneron Pharmaceuticals to develop multispecific antibodies targeting multiple biological pathways simultaneously.
Regeneron's Gene Therapy Shows Remarkable Success in Treating Inherited Deafness
Regeneron's DB-OTO gene therapy demonstrated clinically meaningful hearing improvements in 11 of 12 patients with OTOF gene mutations within weeks of treatment.
Regeneron Presents New Libtayo Data at ESMO 2025, Showcasing Patient-Centric Every 6-Week Dosing for High-Risk Skin Cancer
Regeneron will present new Phase 3 C-POST data at ESMO 2025 demonstrating that an every 6-week dosing regimen for Libtayo (cemiplimab) maintains similar efficacy and safety compared to every 3-week dosing in high-risk cutaneous squamous cell carcinoma patients.